A phase 0/I clnical trial investigating the tolerability and pharmacokinetics of soluble FC-GAMMA IIB receptor SM101 as potential therapy in autoimmune diseases in healthy volunteers.

Trial Profile

A phase 0/I clnical trial investigating the tolerability and pharmacokinetics of soluble FC-GAMMA IIB receptor SM101 as potential therapy in autoimmune diseases in healthy volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 17 Jun 2011

At a glance

  • Drugs SM 101 (Primary)
  • Indications Systemic lupus erythematosus
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 17 Jun 2011 adnms added, start date added etc from 9126093
    • 28 May 2011 Results presented at the 12th Annual Congress of the European League Against Rheumatism.
    • 28 May 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top